0
Y-mAbs Therapeutics, Inc.
- 51-200 Employees
- Based in New York City, New York
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.
Y-mAbs Therapeutics, Inc.
